Clinical trial
Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
NCT02072967 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
- Lead sponsor
- Astellas Pharma Europe B.V.
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2012
- Completion date
- October 31, 2015
- Enrollment
- 97 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.